• 1. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 2. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 3. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acid methyl esters
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acid esters Fatty acid methyl esters
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Recent Advances in the Study of Br-C10-methyl ester (CAS: 6287-90-7) in Chemical Biology and Pharmaceutical Research

Br-C10-methyl ester (CAS: 6287-90-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This compound, characterized by a brominated alkyl chain and a methyl ester functional group, has been explored for its role in modulating biological pathways, particularly in the context of lipid metabolism and membrane dynamics. Recent studies have highlighted its utility as a chemical probe and a potential lead compound for drug development.

One of the key areas of investigation has been the compound's interaction with lipid bilayers and cellular membranes. A 2023 study published in the Journal of Chemical Biology demonstrated that Br-C10-methyl ester exhibits a high affinity for lipid rafts, which are critical for signal transduction and membrane organization. The study utilized fluorescence microscopy and molecular dynamics simulations to elucidate the compound's localization and its impact on membrane fluidity. These findings suggest that Br-C10-methyl ester could serve as a valuable tool for studying membrane-associated processes in diseases such as cancer and neurodegenerative disorders.

In addition to its membrane-related effects, Br-C10-methyl ester has also been investigated for its potential as an enzyme inhibitor. A recent preprint on bioRxiv reported that the compound exhibits inhibitory activity against certain lipases and esterases, which are implicated in metabolic disorders. The study employed kinetic assays and X-ray crystallography to characterize the binding mode of Br-C10-methyl ester, revealing a novel interaction with the active site of these enzymes. This discovery opens new avenues for the development of targeted therapies for conditions like obesity and diabetes.

Another promising application of Br-C10-methyl ester lies in its role as a prodrug. Researchers at the University of Cambridge have explored its conversion into active metabolites in vivo, demonstrating its potential for sustained drug release. A 2024 publication in Pharmaceutical Research detailed the pharmacokinetic profile of Br-C10-methyl ester in rodent models, showing favorable bioavailability and tissue distribution. These findings underscore the compound's potential as a scaffold for prodrug design, particularly for drugs requiring controlled release profiles.

Despite these advancements, challenges remain in the clinical translation of Br-C10-methyl ester. Issues such as off-target effects and metabolic stability need to be addressed through further structure-activity relationship (SAR) studies. Collaborative efforts between academic and industrial researchers are underway to optimize the compound's properties and evaluate its safety profile in preclinical models. The integration of computational modeling and high-throughput screening is expected to accelerate these efforts, paving the way for future clinical trials.

In conclusion, Br-C10-methyl ester (CAS: 6287-90-7) represents a versatile and promising compound in chemical biology and pharmaceutical research. Its unique properties and diverse applications make it a focal point for ongoing studies aimed at understanding its mechanisms of action and therapeutic potential. As research progresses, this compound is likely to play an increasingly important role in the development of novel diagnostics and therapeutics.

• 54049-24-0(Methyl 7-bromoheptanoate)
• 4897-84-1(Br-C3-methyl ester)
• 72338-49-9(Heptadecanoic acid,17-bromo-, methyl ester)
• 71648-29-8(Tetradecanoic acid,bromo-, ethyl ester (9CI))
• 5454-83-1(methyl 5-bromopentanoate)
• 26825-89-8(Hexadecanoic acid, 16-bromo-, methyl ester)
• 26825-92-3(Methyl 8-Bromooctanoate)
• 6271-23-4(Ethyl 11-Bromoundecanoate)
• 14273-90-6(Methyl 6-bromohexanoate)
• 26825-94-5(Methyl 10-Bromodecanoate)